Aquestive Therapeutics Inc (AQST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has a cash flow conversion efficiency ratio of 0.252x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.47 Million) by net assets ($-33.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AQST cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Aquestive Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Aquestive Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aquestive Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aquestive Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangzhou Guotai Environmental Protection Technology Co. Ltd. A
SHE:301203
|
N/A |
|
Restaurant Brands Asia Limited
NSE:RBA
|
0.232x |
|
Zhewen Pictures Group Co Ltd
SHG:601599
|
0.048x |
|
Korea Electric Terminal
KO:025540
|
0.052x |
|
Protec Co. Ltd
KQ:053610
|
-0.031x |
|
JiangSu JiangHuai Engine Co Ltd
SHE:000816
|
0.007x |
|
Chrysos Corporation Ltd
AU:C79
|
0.032x |
|
Viyash Scientific Limited
NSE:SEQUENT
|
0.051x |
Annual Cash Flow Conversion Efficiency for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Aquestive Therapeutics Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see AQST market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-33.66 Million | $-52.43 Million | 1.558x | +162.03% |
| 2024-12-31 | $-60.16 Million | $-35.76 Million | 0.594x | +892.16% |
| 2023-12-31 | $-106.49 Million | $-6.38 Million | 0.060x | -27.44% |
| 2022-12-31 | $-118.55 Million | $-9.79 Million | 0.083x | -79.44% |
| 2021-12-31 | $-82.13 Million | $-32.98 Million | 0.402x | -57.16% |
| 2020-12-31 | $-48.50 Million | $-45.46 Million | 0.937x | -90.47% |
| 2019-12-31 | $-6.12 Million | $-60.21 Million | 9.835x | +863.12% |
| 2018-12-31 | $10.08 Million | $-12.99 Million | -1.289x | -486.31% |
| 2017-12-31 | $-26.50 Million | $5.82 Million | -0.220x | -147.26% |
| 2016-12-31 | $-17.58 Million | $-8.18 Million | 0.465x | +226.96% |
| 2006-12-31 | $25.26 Million | $-9.26 Million | -0.366x | +73.28% |
| 2005-12-31 | $4.67 Million | $-6.39 Million | -1.371x | -- |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more